Last updated: October 29, 2026
Chlorpropamide is a first-generation sulfonylurea for type 2 diabetes that has lost commercial relevance in the United States. Its market declined after newer sulfonylureas, metformin, insulin analogs, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors displaced it. The active ingredient has no meaningful remaining exclusivity barrier, no material biosimilar issue, and limited evidence of current branded sales. Financial value is concentrated in low-cost generic supply, legacy regulatory files, and selected markets where older oral antidiabetic products remain available.
What is chlorpropamide and how was it commercialized?
Chlorpropamide is an oral sulfonylurea that stimulates pancreatic insulin secretion. It was developed for adults with type 2 diabetes and marketed in the United States under the brand name Diabinese. Pfizer commercialized Diabinese during the early era of oral diabetes treatment.
The product received U.S. approval in the late 1950s. Historical medical references identify chlorpropamide as one of the earliest widely used second-generation sulfonylureas, although it is now rarely selected because of its long half-life and adverse-effect profile, particularly prolonged hypoglycemia and hyponatremia caused by inappropriate antidiuretic hormone secretion.[1][2]
| Attribute |
Chlorpropamide |
| Active ingredient |
Chlorpropamide |
| Drug class |
First-generation sulfonylurea |
| Primary indication |
Type 2 diabetes mellitus |
| Historical U.S. brand |
Diabinese |
| Historical brand company |
Pfizer |
| Common dosage form |
Oral tablet |
| Typical strengths |
100 mg and 250 mg |
| FDA status |
Legacy approved product; branded commercial relevance has ended |
| ATC classification |
A10BB01 |
| Current clinical position |
Rarely used; generally displaced by newer agents |
Chlorpropamide is not an insulin, biologic, or complex delivery product. Its commercial model depends on conventional tablet manufacturing and active pharmaceutical ingredient supply.
When did chlorpropamide lose exclusivity?
Chlorpropamide lost meaningful commercial exclusivity decades ago. Any original composition-of-matter or product protection associated with the historical Diabinese product would have expired long before the modern generic market developed.
The product has no commercially relevant current patent barrier in the United States. The applicable competitive risk is therefore generic substitution, not patent expiry timing.
What patents protect chlorpropamide?
No active U.S. patent is generally recognized as protecting chlorpropamide as a marketed product. Historical patents covering the active compound or the original product would have expired many years ago under the patent terms applicable when they were issued.
There is no known modern patent estate covering:
- A novel chlorpropamide molecule;
- A protected crystalline form with meaningful market exclusivity;
- A differentiated extended-release formulation;
- A current branded combination product;
- A biologic or biosimilar reference product.
The Orange Book remains the principal FDA source for determining listed patents and regulatory exclusivity for approved small-molecule products. A current commercial review would focus on whether any active abbreviated new drug application, listed patent, or regulatory exclusivity remains associated with a specific chlorpropamide product rather than with the molecule generally.[3]
What is the FDA regulatory status of chlorpropamide?
Chlorpropamide is a legacy FDA-approved oral antidiabetic. Its practical U.S. status is defined by limited current availability and weak commercial demand rather than by regulatory exclusivity.
FDA labeling identifies several clinically important risks:
- Prolonged hypoglycemia;
- Hypoglycemia in elderly patients and patients with impaired renal function;
- Hyponatremia associated with inappropriate antidiuretic hormone secretion;
- Alcohol-related disulfiram-like reactions;
- Reduced usefulness when pancreatic beta-cell function is substantially impaired.[2]
The long pharmacologic duration creates a larger safety-management burden than shorter-acting alternatives. That risk profile has reduced its attractiveness to prescribers even where the product remains technically obtainable.
Does chlorpropamide have FDA exclusivity?
No meaningful FDA exclusivity period remains. Any new-drug exclusivity associated with the original approval expired many decades ago. Chlorpropamide has no current orphan-drug, pediatric, new chemical entity, or biologic exclusivity.
What is the Orange Book status of chlorpropamide?
The Orange Book status depends on the specific product and manufacturer record. Chlorpropamide has no commercially significant current Orange Book patent position comparable to newer branded diabetes products.
The relevant distinction is between:
- Historical approval of the active ingredient;
- Current marketing status of an individual tablet product;
- Patent listings for a particular NDA;
- Availability of generic products under ANDAs.
A discontinued or inactive branded NDA does not create market protection. It can indicate that the original sponsor no longer maintains a commercial position, while generic or foreign-market products may continue under separate regulatory files.
How large is the current chlorpropamide market?
The current chlorpropamide market is niche and fragmented. Public company filings generally do not report chlorpropamide revenue separately because sales, if any, are immaterial relative to portfolios containing newer diabetes products.
The market has the following characteristics:
| Market factor |
Current effect |
| Patient demand |
Low and declining in developed markets |
| Prescriber demand |
Limited by safety and tolerability concerns |
| Pricing power |
Minimal |
| Generic competition |
High where products are available |
| Brand premium |
Essentially absent |
| Manufacturing complexity |
Low |
| Regulatory burden |
Moderate because of legacy safety concerns |
| Revenue visibility |
Poor; product-level sales are rarely disclosed |
| Growth outlook |
Negative or flat at a very small base |
Chlorpropamide may retain limited use in countries where low-cost oral therapy is prioritized and the drug remains registered. That use does not create a substantial global opportunity because sulfonylureas with shorter duration, metformin, and newer therapies are widely available.
What is the financial trajectory for chlorpropamide?
Chlorpropamide’s financial trajectory has passed through four stages:
| Period |
Financial trajectory |
Main driver |
| Late 1950s to 1970s |
Growth |
Expansion of oral diabetes treatment |
| 1980s to 1990s |
Decline begins |
Competition from newer sulfonylureas and metformin |
| 2000s |
Steep contraction |
Expansion of branded modern diabetes therapies |
| 2010s onward |
Low-value generic niche |
Residual demand and limited-market supply |
The original commercial opportunity was created by the shift from insulin-only treatment toward oral therapy. That opportunity contracted as treatment standards changed. Metformin became a preferred first-line agent in many guidelines, while later therapies offered lower hypoglycemia risk, weight benefits, cardiovascular advantages, or better dosing flexibility.
No reliable public source provides a current standalone revenue series for chlorpropamide. Pfizer’s historical financial reporting did not create a durable, product-level revenue record that supports a modern valuation model. Generic suppliers also typically report portfolio revenue without disclosing unit sales or margin data for chlorpropamide.
The commercial value of a chlorpropamide product is therefore more likely to come from:
- Existing regulatory approval;
- Access to a low-cost API supplier;
- Manufacturing capacity;
- Distribution in countries where demand persists;
- Portfolio economics from bundling the product with other generic medicines.
A standalone launch in the United States would likely face limited volume, low pricing, and substantial regulatory maintenance cost relative to expected revenue.
Which companies are challenging chlorpropamide’s market?
The principal competitive threat is not a named challenger but therapeutic substitution. Chlorpropamide competes with multiple drug classes:
| Competitor |
Competitive advantage over chlorpropamide |
| Metformin |
Established first-line status and low cost |
| Glipizide |
Shorter duration and lower concern about prolonged hypoglycemia |
| Glyburide |
Similar class but often preferred where chlorpropamide is unavailable |
| Glimepiride |
Once-daily dosing and broader modern use |
| DPP-4 inhibitors |
Lower hypoglycemia risk as monotherapy |
| GLP-1 receptor agonists |
Weight reduction and cardiometabolic benefits |
| SGLT2 inhibitors |
Cardiovascular and renal outcome advantages |
| Insulin products |
Greater glucose-lowering capacity in advanced disease |
The competitive landscape has reduced both initiation and continuation of chlorpropamide therapy. A prescriber selecting a sulfonylurea generally has access to alternatives with more manageable pharmacokinetics.
What formulations are protected by chlorpropamide patents?
No commercially material chlorpropamide formulation patent is known to protect the current market. The conventional immediate-release tablet is technically simple and can be manufactured by standard wet-granulation, dry-granulation, or direct-compression processes, subject to product-specific controls.
Potential technical barriers include:
- API impurity control;
- Assay and content uniformity;
- Tablet dissolution;
- Stability under heat and humidity;
- Packaging that limits moisture exposure;
- Bioequivalence documentation;
- Validation of manufacturing changes.
These are manufacturing and regulatory requirements, not durable exclusivity rights.
An extended-release or modified-release chlorpropamide product could theoretically create differentiation, but such a product would require clinical, pharmacokinetic, safety, and regulatory support. The long half-life and hypoglycemia risk would weaken the commercial case for investing in a reformulation.
Are there Paragraph IV challenges for chlorpropamide?
A contemporary Paragraph IV challenge is unlikely to be commercially relevant. Paragraph IV litigation is generally used when a generic applicant challenges an active patent listed for an approved reference product. Chlorpropamide lacks a meaningful current patent position that would support a major U.S. litigation campaign.
The likely entry pathways are:
- Generic approval where an active reference product and regulatory pathway remain available;
- Reintroduction through a new or revived manufacturer-specific application;
- Import or local registration in foreign markets;
- Continued supply from existing generic manufacturers.
Because the molecule is old and the formulation is simple, the principal risk is regulatory and commercial execution rather than patent invalidity or non-infringement litigation.
What patent litigation affects chlorpropamide?
No material current U.S. patent litigation involving chlorpropamide is prominent in the public pharmaceutical litigation landscape. There is no comparable litigation profile to drugs such as semaglutide, tirzepatide, empagliflozin, or branded insulin products.
Historical disputes, if any, would have limited relevance to present valuation because the original patent term has ended and the market has moved to low-margin generic supply.
Are there licensing deals for chlorpropamide?
No major current licensing transaction centered on chlorpropamide is publicly evident. The product was historically associated with Pfizer through Diabinese, but that relationship does not represent an active growth platform.
Any current licensing economics would likely involve:
- Transfer of a legacy regulatory file;
- Local marketing rights;
- Supply agreements;
- Contract manufacturing;
- API sourcing;
- Portfolio acquisitions of older generic products.
A chlorpropamide licensing deal would have limited strategic value unless it included a broader diabetes portfolio, established distribution rights, or a low-cost manufacturing platform.
What generic launch scenarios exist for chlorpropamide?
U.S. re-entry scenario
A U.S. re-entry could occur if a sponsor identifies sufficient demand, completes the required regulatory work, and secures reliable API supply. The commercial model would be constrained by low prescription volume and reimbursement pressure.
Emerging-market continuation scenario
The more plausible scenario is continued availability in selected emerging markets. Local manufacturers may retain the product because of low production cost, established prescribing habits, and demand for inexpensive oral therapy.
Reformulation scenario
A modified-release or combination product could theoretically support differentiation, but development risk would be high. The safety profile of chlorpropamide would make regulators and prescribers cautious about increasing exposure duration.
Discontinuation scenario
Further market withdrawal is the most likely long-term direction in jurisdictions where treatment guidelines and formularies favor newer agents. Discontinuation can occur because of low demand, API sourcing problems, manufacturing economics, or quality-system costs rather than patent expiry.
How strong is the chlorpropamide patent estate?
The patent estate is commercially weak.
| Patent-estate category |
Assessment |
| Composition of matter |
Expired |
| Original product protection |
Expired |
| Formulation patents |
No material current protection identified |
| Method-of-use patents |
No relevant current exclusivity identified |
| Regulatory exclusivity |
Expired |
| Manufacturing patents |
No material market barrier identified |
| Geographic exclusivity |
Depends on local registration, not global IP |
| Litigation leverage |
Minimal |
The product’s residual defensibility comes from regulatory know-how, supply continuity, and market access. Those assets can support a small generic business but cannot sustain premium pricing.
What geographic markets still matter for chlorpropamide?
Geographic demand is likely concentrated in markets where older sulfonylureas remain available and treatment costs are tightly controlled. Developed markets have stronger substitution pressure from metformin, modern sulfonylureas, and newer therapies.
Commercial evaluation should distinguish between:
- Product registration;
- Actual distribution;
- Reimbursement;
- Prescriber use;
- Hospital or tender demand;
- API availability;
- Local quality requirements.
A product may remain registered without generating material sales. Conversely, a small market can remain commercially viable if a manufacturer has low fixed costs and an established local distribution network.
Key Takeaways
- Chlorpropamide is a legacy oral sulfonylurea with low and declining commercial demand.
- The original Diabinese franchise no longer has meaningful brand or patent protection.
- No current U.S. patent estate creates a material entry barrier.
- Paragraph IV litigation and settlement risk are minimal compared with modern branded diabetes products.
- Generic supply, not innovation, defines the remaining market.
- Public company filings do not provide a reliable current standalone revenue series.
- The strongest residual opportunity is a low-cost, portfolio-based generic strategy in selected international markets.
- A U.S. re-entry would face weak volume, low pricing, safety concerns, and limited prescriber demand.
- Biosimilar risk is irrelevant because chlorpropamide is a small-molecule drug, not a biologic.
- Long-term market direction is continued contraction or localized persistence.
FAQs
Is chlorpropamide still sold in the United States?
Chlorpropamide has little practical U.S. commercial presence. The historical Diabinese brand is no longer a meaningful U.S. growth product, and availability of generic tablets is limited and manufacturer-dependent.
Why was chlorpropamide replaced by newer diabetes drugs?
Its long duration increases the risk of prolonged hypoglycemia. It also has adverse-effect concerns, including hyponatremia. Metformin and newer therapies generally offer better treatment positioning and more favorable risk-benefit profiles.
Does chlorpropamide have any remaining patent protection in Europe?
No broad, commercially meaningful European patent protection should be expected for the original molecule or conventional tablet. Local registration and national regulatory status determine whether a product can still be marketed.
Can a company launch a new chlorpropamide formulation?
A company could pursue a new formulation, but it would need to justify the clinical and commercial value of the product. The active ingredient’s long half-life and safety profile would make a modified-release strategy difficult to differentiate.
Is chlorpropamide a viable acquisition target?
As a standalone asset, chlorpropamide has limited acquisition value. It may have value within a broader legacy-generic portfolio if the transaction includes established registrations, low-cost manufacturing, distribution rights, or access to markets where demand persists.
References
-
National Center for Biotechnology Information. (2023). Chlorpropamide. In LiverTox: Clinical and research information on drug-induced liver injury. U.S. National Library of Medicine.
-
DailyMed. (n.d.). Chlorpropamide tablet prescribing information. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: Chlorpropamide, A10BB01. WHO.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
